Favorability ratings were essentially even for Walz in a new KARE 11-MPR News-Minnesota Star Tribune Minnesota Poll.

A new KARE 11-MPR News-Minnesota Star Tribune Minnesota Poll shows the Democratic ticket with a five-point lead for Minnesota ...

While neoadjuvant therapy in stage III or great melanoma is already the standard of care, new research presented at ESMO ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...

A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD.

Prior to 2020 those rates were all closer to 95%. University of Minnesota public health expert Michael Osterholm told MPR ...

The FDA has approved Rybrevant in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ...

Information about the poll methodology, demographics of the respondents and a map of the geographic regions for this week’s Star Tribune/MPR News/KARE 11 Minnesota Poll.

What is the current share price of MPower Group Limited (MPR)? MPower Group Limited's (MPR) current share price is $0.01. This constitutes a price movement of 0% when compared to the share price 7 ...

In apparent speculation over the direction of the monetary policy as the Monetary Policy Committee, MPC of the Central Bank ...

1 The trial found that such an approach was associated with a high major pathological response (MPR) rate (35 [76%, 95% CI 61–87] of 46 patients), meaning it met its prespecified primary endpoint, and ...

01NICHE-2试验在2024年欧洲肿瘤内科学会 (ESMO)年会上报告了非转移性晚期错配修复功能缺陷 (dMMR)结肠癌患者的新辅助治疗结果，3年无病生存率达100%。